Quest Laboratories Limited IPO
Quest Laboratories Limited is a pharmaceutical company engaged in the development, manufacturing, and distribution of a diverse range of pharmaceutical formulations. These products encompass antibiotics, antimalarials, antispasmodics, anti-inflammatories, antidepressants, respiratory medications, and more. They are available in different forms like tablets, oral liquids, dry powders, and ointments. All formulations are marketed under the brand name “Quest Laboratories Limited,” covering ethical, generic, and over-the-counter drugs. This comprehensive product range addresses diverse medical needs and patient preferences.
Market Strategy:
i. Quest Laboratories serves both government and private institutions through collaborative approaches that offer benefits like regulatory compliance, cost efficiency, access to specialized technologies, reduced lead times, and risk mitigation.
ii. The company has successfully bid for government contracts with major central and state institutions.
iii. They currently serve 12 states and 2 union territories, focusing on a steady supply chain through relationships with reliable suppliers across several Indian regions.
Product Development and R&D:
i. Quest Laboratories constantly expands its product portfolio through research and development. The company has an in-house department dedicated to formulation development, quality control, and product stability studies.
ii. The R&D team conducts validation processes to ensure that their formulations meet regulatory standards and customer expectations.
Government Support:
Quest Laboratories has benefited from several government initiatives, such as the Madhya Pradesh MSME Yojna and MSME Promotion Schemes, providing subsidies for capital investments in machinery and interest payments. This support has enabled the company to grow its operations, enhance productivity, and create jobs.
Quest Laboratories Limited’s comprehensive business model, backed by certifications, quality control, R&D, government support, and a highly skilled management team, enables it to meet the diverse needs of the domestic and international pharmaceutical market.
Objects of the Quest Laboratories Limited IPO:
Quest Laboratories Limited IPO Details:
Open Date: | May 15 2024 |
Close Date: | May 17 2024 |
Total Shares: | 4,449,600 |
Face Value: | ₹ 10 Per Equity Share |
Issue Size: | 43.16 Cr. |
Lot Size: | 1200 Shares |
Issue Price: | ₹ 93 - 97 Per Equity Share |
Listing At: | NSE Emerge |
Listing Date: | May 23 2024 |
Promoters And Management:
Financials of Quest Laboratories Limited IPO:
Particulars ( In Lakhs ) |
2021 |
2022 |
2023 |
9M-FY24 |
Revenue from Operations | 3,036 | 5,948 | 6,164 | 6,208 |
Other Income | 7 | 6 | 23 | 10 |
Total Revenue | 3,044 | 5,954 | 6,187 | 6,218 |
Cost of Material Consumed | 2,443 | 4,427 | 4,174 | 3,996 |
Change in Inventories | 3 | 22 | 8 | -10 |
Employees Benefit Expenses | 253.1 | 346 | 357 | 330 |
Other Expenses | 195 | 506 | 843 | 683 |
EBITDA | 149 | 652 | 805 | 1,218 |
Depreciation & Amortisation | 39 | 46 | 55 | 42 |
Finance Cost | 31 | 30 | 54 | 63 |
EBIT | 110 | 606 | 750 | 1,177 |
OPM (%) | 4.90% | 10.96% | 13.01% | 19.60% |
PBT | 79 | 577 | 696 | 1114 |
Tax | 13 | 166 | 193 | 339 |
PAT | 66 | 411 | 503 | 775 |
NPM (%) | 2.15% | 6.89% | 8.13% | 12.46% |
No.of Shares | 163.87 | 163.87 | 163.87 | 163.87 |
EPS | 0.39 | 2.50 | 3.06 | 4.72 |
Comparison With Peers:
Name of the Company | Revenue (In Crore) | PAT (In Crore) | EPS ( in Rs) | P/E | CMP | Mcap (In Crore) |
Quest Laboratories Limited | 62 | 5 | 3.06 | 31.6 | 97 | 159 |
Beta Drugs Limited | 227 | 31 | 31.95 | 35.0 | 1,263 | 1,214 |
Alpa Laboratories Limited | 93 | 13 | 6.00 | 10.6 | 90.2 | 190 |
Zenith Drugs Limited | 114 | 5 | N/A | 20.6 | 62 | 106 |
Recommendation on Quest Laboratories Limited IPO:
Lead Manager of Quest Laboratories Limited IPO:
Registrar of Quest Laboratories Limited IPO:
Company Address:
Discussion on Quest Laboratories Limited IPO:
Leave a Reply
You must be logged in to post a comment.